Skip NavigationSkip to Content

NCI at Frederick Scientific Publications Advanced Search

Search

  1. NCI-F Publications

  2. Return to Quick Search
Search
  2. Year Published:

Your search returned 17 results.
User Information
Export Records
  1. 1.   Integrated miRNA and mRNA expression profiling of mouse mammary tumor models identifies miRNA signatures associated with mammary tumor lineage
  2. Zhu, M.; Yi, M.; Kim, C. H.; Deng, C. X.; Li, Y.; Medina, D.; Stephens, R. M.; Green, J. E.
  3. Genome Biology. 2011, Aug 16; 12(8): 16.
  1. 2.   Two-tiered Approach Identifies a Network of Cancer and Liver Disease-related Genes Regulated by miR-122
  2. Boutz, D. R.; Collins, P. J.; Suresh, U.; Lu, M. Z.; Ramirez, C. M.; Fernandez-Hernando, C.; Huang, Y. F.; Abreu, R. D.; Le, S. Y.; Shapiro, B. A.; Liu, A. M.; Luk, J. M.; Aldred, S. F.; Trinklein, N. D.; Marcotte, E. M.; Penalva, L. O. F.
  3. Journal of Biological Chemistry. 2011, May; 286(20): 18066-18078.
  1. 3.   Identifying functional miRNA-mRNA regulatory modules with correspondence latent dirichlet allocation
  2. Liu, B.; Liu, L.; Tsykin, A.; Goodall, G. J.; Green, J. E.; Zhu, M.; Kim, C. H.; Li, J. Y.
  3. Bioinformatics. 2010, Dec; 26(24): 3105-3111.
  1. 4.   The role of miR-31 and its target gene SATB2 in cancer-associated fibroblasts
  2. Aprelikova, O.; Yu, X. A.; Palla, J.; Wei, B. R.; John, S.; Yi, M.; Stephens, R.; Simpson, R. M.; Risinger, J. I.; Jazaeri, A.; Niederhuber, J.
  3. Cell Cycle. 2010, Nov; 9(21): 4387-4398.
  1. 5.   CCAAT/enhancer binding protein delta (C/EBP delta, CEBPD)-mediated nuclear import of FANCD2 by IPO4 augments cellular response to DNA damage
  2. Wang, J.; Sarkar, T. R.; Zhou, M.; Sharan, S.; Ritt, D. A.; Veenstra, T. D.; Morrison, D. K.; Huang, A. M.; Sterneck, E.
  3. Proceedings of the National Academy of Sciences of the United States of America. 2010, Sep; 107(37): 16131-16136.
  1. 6.   Integrating data on DNA copy number with gene expression levels and drug sensitivities in the NCI-60 cell line panel
  2. Bussey, K. J.; Chin, K.; Lababidi, S.; Reimers, M.; Reinhold, W. C.; Kuo, W. L.; Gwadry, F.; Jain, A.; Kouros-Mehr, H.; Fridly, J.; Jain, A.; Collins, C.; Nishizuka, S.; Tonon, G.; Roschke, A.; Gehlhaus, K.; Kirsch, I.; Scudiero, D. A.; Gray, J. W.; Weinstein, J. N.
  3. Molecular Cancer Therapeutics. 2006, Apr; 5(4): 853-867.
  1. 7.   Precancer in mice: Animal models used to understand, prevent, and treat human precancers
  2. Cardiff, R. D.; Anver, M. R.; Boivin, G. P.; Bosenberg, M. W.; Maronpot, R. R.; Molinolo, A. A.; Nikitin, A. Y.; Rehg, J. E.; Thomas, G. V.; Russell, R. G.; Ward, J. M.
  3. Toxicologic Pathology. 2006 34(6): 699-707.
  1. 8.   Synthesis of a C-terminally biotinylated macrocyclic peptide mimetic exhibiting high Grb2 SH2 domain-binding affinity
  2. Shi, Z. D.; Liu, H. P.; Zhang, M. C.; Worthy, K. M.; Bindu, L.; Yang, D. J.; Fisher, R. J.; Burke, T. R.
  3. Bioorganic & Medicinal Chemistry. 2005, JUL 1; 13(13): 4200-4208.
  1. 9.   Ring-closing metathesis of C-terminal allylglycine residues with an N-terminal beta-vinyl-substituted phosphotyrosyl mimetic as an approach to novel Grb2 SH2 domain-binding macrocycles
  2. Oishi, S.; Shi, Z. D.; Worthy, K. M.; Bindu, L. K.; Fisher, R. J.; Burke, T. R.
  3. Chembiochem. 2005, APR; 6(4): 668-674.
  1. 10.   Utilization of a nitrobenzoxadiazole (NBD) fluorophore in the design of a Grb2 SH2 domain-binding peptide mimetic
  2. Shi, Z. D.; Karki, R. G.; Oishi, S.; Worthy, K. M.; Bindu, L. K.; Dharmawardana, P. G.; Nicklaus, M. C.; Bottaro, D. P.; Fisher, R. J.; Burke, T. R.
  3. Bioorganic & Medicinal Chemistry Letters. 2005, MAR 1; 15(5): 1385-1388.
  1. 11.   Design and synthesis of conformationally constrained Grb2 SH2 domain binding peptides employing alpha-methylphenylalanyl based phosphotyrosyl mimetics
  2. Oishi, S.; Karki, R. G.; Kang, S. U.; Wang, X. Z.; Worthy, K. M.; Bindu, L. K.; Nicklaus, M. C.; Fisher, R. J.; Burke, T. R.
  3. Journal of Medicinal Chemistry. 2005, FEB 10; 48(3): 764-772.
  1. 12.   Evaluation of macrocyclic Grb2 SH2 domain-binding peptide mimetics prepared by ring-closing metathesis of C-terminal allylglycines with an N-terminal beta-vinyl-substituted phosphotyrosyl mimetic
  2. Oishi, S.; Karki, R. G.; Shi, Z. D.; Worthy, K. M.; Bindu, L.; Chertov, O.; Esposito, D.; Frank, P.; Gillette, W. K.; Maderia, M.; Hartley, J.; Nicklaus, M. C.; Barchi, J. J.; Fisher, R. J.; Burke, T. R.
  3. Bioorganic & Medicinal Chemistry. 2005 13(7): 2431-2438.
  1. 13.   A novel macrocyclic tetrapeptide mimetic that exhibits low- picomolar Grb2 SH2 domain-binding affinity
  2. Shi, Z. D.; Lee, K.; Liu, H. P.; Zhang, M. C.; Roberts, L. R.; Worthy, K. M.; Fivash, M. J.; Fisher, R. J.; Yang, D. J.; Burke, T. R.
  3. Biochemical and Biophysical Research Communications. 2003 310(2): 378-383.
  1. 14.   Overexpression of Grb2 in inflammatory lesions and preneoplastic foci and tumors induced by N-nitrosodimethylamine in helicobacter hepaticus-infected and -noninfected A/J mice
  2. Diwan, B. A.; Ramakrishna, G.; Anderson, L. M.; Ramljak, D.
  3. Toxicologic Pathology. 2000 28(4): 548-554.
  1. 15.   Dominant negative Met reduces tumorigenicity-metastasis and increases tubule formation in mammary cells
  2. Firon, M.; Shaharabany, M.; Altstock, R. T.; Horev, J.; Abramovici, A.; Resau, J. H.; Vande Woude, G. F.,; Tsarfaty, I.
  3. Oncogene. 2000 19(20): 2386-2397.
  1. 16.   Induction of proliferative lesions of the uterus, testes, and liver in Swiss mice given repeated injections of sodium arsenate: Possible estrogenic mode of action
  2. Waalkes, M. P.; Keefer, L. K.; Diwan, B. A.
  3. Toxicology and Applied Pharmacology. 2000 166(1): 24-35.
  1. 17.   Phase I and pharmacokinetic study of farnesyl protein transferase inhibitor R115777 in advanced cancer
  2. Zujewski, J.; Horak, I. D.; Boland, C. J.; Woestenborghs, R.; Bowden, C.; End, D. W.; Piotrovsky, V. K.; Chiao, J.; Belly, R. T.; Todd, A.; Kopp, W. C.; Kohler, D. R.; Chow, C.; Noone, M.; Hakim, F. T.; Larkin, G.; Gress, R. E.; Nussenblatt, R. B.; Kremer, A. B.; Cowan, K. H.
  3. Journal of Clinical Oncology. 2000 18(4): 927-941.
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel